Skip to main content

Share story

Capital

New Sequoia leadership greenlights first Anthropic investment amid $25 billion raise

New Sequoia leadership greenlights first Anthropic investment amid $25 billion raise Image: Primary
Sequoia Capital is making its first investment in Anthropic. The funding round would value the AI company at $350 billion. The investment comes after a leadership change at the California-based venture capital firm, according to a Financial Times report. The round is led by Singapore's sovereign wealth fund GIC and US investor Coatue, each contributing $1.5 billion. Anthropic is targeting a total raise of $25 billion. Microsoft and Nvidia have committed to investing up to $15 billion combined, with additional VC firms and investors expected to contribute $10 billion or more. New leadership at Sequoia has greenlit the investment. Former chief Roelof Botha had avoided Anthropic investments and warned against concentrating venture capital in a handful of highly valued startups. He was ousted in November, with Pat Grady and Alfred Lin taking over. Sequoia has already invested in OpenAI and Elon Musk's xAI. According to a person familiar with Sequoia, the round has grown so large that it has shifted from a traditional venture capital investment to something closer to an equity investment.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from The Decoder and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.